Q-FASTR Development Award
Funds Harvard biomedical investigators through sustained support to reach preclinical milestones.
The Q-FASTR Development Award is the larger of two grant tracks administered by Q-FASTR (Quadrangle Fund for Advancing and Seeding Translational Research) at Harvard Medical School's Innovation Hub, established in 2014 with initial support from Phill Gross and matched funding from the Warren Alpert Foundation and Barbara and Louis Perlmutter. Development Awards provide up to $300,000 in direct cos…
Advanced-stage preclinical development: chemical or biological compounds showing activity in validated preclinical models, with a clear path to clinical or commercial development.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Guides for this application
All guides →Grants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
DocumentsGrant Work Plan Template: Work Packages, Gantt, Milestones, and Risks
Use this grant work plan template to structure work packages, tasks, owners, deliverables, Gantt timing, dependencies, and risk registers.
Submit & reportGrant Reporting Requirements: Post-Award Reports and Compliance
Learn what grant reporting requirements cover, how financial and performance reports work, what to track after an award, and how to avoid post-award compliance mistakes.
Write proposalGrant Concept Note Example: Pre-Proposal Structure for Startups
See a practical grant concept note example, with a worked deeptech pre-proposal, section map, invite-to-full logic, and reviewer checks.
More from Q-FASTR
All grants from this funder →Similar grants
Browse the directory →
NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NCATS Preclinical Proof of Concept Studies for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies conducting preclinical efficacy studies to advance therapeutic candidates for rare diseases toward IND applications.
NSF STTR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups partnering with nonprofit research institutions for early-stage feasibility studies.
NCATS STTR Phase I
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to conduct feasibility studies on translational science innovations toward commercialization.
NSF SBIR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups demonstrating scientific feasibility of novel science and engineering innovations.
NIH SBIR Phase I
🇺🇸NIH SEED · United States
Funds early stage United States biomedical teams through NIH seed support for feasibility work on prototype ready ideas.